TITLE

WuXi PharmaTech, PBI In Biomarker Alliance

PUB. DATE
April 2014
SOURCE
Contract Pharma;Apr2014, Vol. 16 Issue 3, p36
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the collaboration between research and development (R&D) services company WuXi PharmaTech and biomarker laboratory services provider Pacific Biomarkers (PBI), in which the latter will provide validated biomarker assays for the clinical trial testing services of WuXi.
ACCESSION #
95412191

 

Related Articles

  • Wuxi Pharmatech. Investor's Business Daily // Investors Business Daily;8/19/2014, pA02 

    The article reports on an announcement by Wuxi Pharmatech Inc. regarding the passing of the U.S. Food and Drug Administration (FDA) inspection by its Shanghai SynTheAll Pharmaceutical subsidiary.

  • BofA, JPM Arrange $1.25B CF for Pharma Acquisition. Kellerhals, Richard // High Yield Report;5/3/2010, Vol. 21 Issue 18, p9 

    The article reports on a 1.26 billion U.S.-dollar credit facility arranged by the banks Bank of America Merrill Lynch and JP Morgan for the acquisition of WuXi PharmaTech by fellow pharmaceutical research company Charles River Labs.

  • WuXi PharmaTech, PRA Form Chinese Market JV.  // Contract Pharma;Jan/Feb2013, Vol. 15 Issue 1, p87 

    The article reports on the joint venture agreement of WuXi PharmaTech Inc. and PRA to offer clinical trial services in China, Hong Kong and Macau.

  • Acetaminophen deal.  // Chemical Week;1/29/97, Vol. 159 Issue 4, p48 

    Reports on A.F. Pharmaceuticals' contract as exclusive distributor of Wuxi C.S.I. Pharmaceutical's acetaminophen product.

  • WUXI PHARMATECH. Investor's Business Daily // Investors Business Daily;5/15/2014, pA02 

    The article reports on the financial performance of Wuxi PharmaTech Inc. for the first quarter (Q1) 2014 which indicates a 14% decline in stock prices.

  • WUXI PHARMA TECH.  // Acquisdata Company SnapShot: WuXi PharmaTech;11/9/2015, Issue 493, preceding p1 

    The article profiles global contract research and development (R&D) services provider WuXi PharmaTech, which include financial statement for the third quarter of 2015, generally accepted accounting principles (GAAP) and non-GAAP income, and its competitors.

  • CROs/Service Providers.  // CenterWatch Weekly;12/12/2015, Vol. 19, p2 

    The article offers pharmaceutical industry news briefs as of December 21, 2015 on topics including Integrated Asset Development Plan (IADP) from Quintiles and joint venture between research and development firm WuXi PharmaTech and research organization PRA Health Science.

  • WUXI PHARMATECH. Investor's Business Daily // Investors Business Daily;11/13/2014, pA02 

    The article reports that Chinese medical contract researcher Wuxi Pharmatech Inc. has posted an increase in earnings per share in the third quarter of 2014 due to the significant increase in sales.

  • ELI LILLY. Investor's Business Daily // Investors Business Daily;11/11/2015, pA02 

    The article reports on the partnership of WuXi PharmaTech, research and development services company, and pharmaceutical firm Eli Lilly & Co. to develop a drug for cardiovascular disease in dyslipidemia patients.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics